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Abstract 108 – Table 1. Adjusted* Hazard Ratios for TGF-β1 and OA Outcomes
Deﬁnition of OA Outcomes n Adjusted HR* p value
(knees with outcome) (95%CI)
Incident rOA (from baseline K-L<2 to K-L ≥ 2) 103 1.10 (0.46-2.63) 0.83
Incident rOA (from baseline K-L<1 to K-L ≥ 1) 94 1.04 (0.41-2.65) 0.93
Incident OST (from grade 0 to grade ≥ 1) 94 1.41 (0.56-3.56) 0.47
Incident JSN (from grade 0 to grade ≥ 1) 99 1.39 (0.50-3.88) 0.53
Progressive rOA (increasing ≥ 1 grade from baseline K-L ≥ 2) 86 1.36 (0.63-2.91) 0.44
Progressive rOA (increasing ≥ 1 grade from baseline K-L ≥ 1) 160 1.51 (0.82-2.79) 0.19
Progressive OST (increasing ≥ 1 grade from baseline OST ≥ 1) 76 0.55 (0.24-1.26) 0.16
Progressive JSN (increasing ≥ 1 grade from baseline JSN ≥ 1) 84 1.40 (0.64-3.03) 0.40
*Adjusted for age, race, gender, and body mass index.
6.1±1.3 years. There were no signiﬁcant interactions by race or
gender. The hazard ratios (Table) show no signiﬁcant relationships
between higher serum TGF-β1 and incident rOA, OST, or JSN
at the knee before or after adjustment. The odds of progressive
rOA by either K-L deﬁnition were 40- 50% higher in association
with higher serum TGF-β1 levels, but this association was not
statistically signiﬁcant. There was an apparent reduction in OST
progression with higher lnTGF-β1, also not statistically signiﬁcant.
Conclusions: Serum TGF-β1 levels do not predict development
of incident rOA, OST, or JSN in this longitudinal, population-based
study including AA and Caucasian men and women. The ﬁnding of
increased rOA K-L progression with higher serum TGF-β1 levels
did not reach statistical signiﬁcance, even in this largest study to
date of this biomarker, making it unlikely that serum TGF-β1 will
be a robust, stand-alone biomarker for future studies.
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Purpose: Type II collagen is the major collagen of the articular
cartilage and it is gradually degraded during the pathogenesis of
osteoarthritis (OA). Measurement of collagen type II degradation
fragments may be associated with the progression of Osteoarthritis
(OA). It is appreciated that aggrecan degradation is a combina-
tion of MMP and aggrecanase activity, resulting in a distinct and
protease speciﬁc temporal release pattern, with aggrecanase ac-
tivity at early time-points and MMP activity at later time-points.
The release of collagen type II is less understood with respect
to the temporal release pattern, and the different proteolytic pro-
teases associated with that. We therefore identiﬁed three novel
MMP-mediated collagen type II degradation fragments of collagen
type II, and developed assays for that. We compared the release
pattern to that of CTX-II.
Methods: Human type II collagen (puriﬁed) and human articu-
lar cartilage was digested with a mix of MMPs. The digested
was analyzed on LC-MS/MS and peptide fragments were identi-
ﬁed/mapped by Mascot database search. Three neoepitopic se-
quences were chosen, synthesized and used as immunogen.
Fusions were made from the spleen of good-titer mice. After
cloning and screening, the best clones were chosen and the
monoclonal antibodies were puriﬁed and entered assay devel-
opment. All assays were designed as follows: 1) biotin-peptid
on streptavidin plates, 2) samples or standard, 3) Primary anti-
body, and 4) secondary HRP-antibody. Bovine explants cultures
treated with proinﬂammatory cytokines were used for testing the
biomarkers for native reactivity. Experiment including different pro-
teases inhibitors were conducted to validated the origin of the new
biomarkers. Established markers were measured in paralled for
comparison. Furthermore; the antibodies were tested for localiza-
tion by immunohistochemistry.
Results: Three assays were developed; CIIM538, CIIM1027 and
CIIM1053. All three assays were optimized in respect to incubation
buffer, time and temperature, as well as antibody concentrations.
Following technical speciﬁcation were established (on average):
Range - 1-500 ng/ml, lower detection limit 0.2 ng/ml, dilution recov-
ery 95-120%, intra- and inter-assay CVs < 6% and 11%, respec-
tively. Measuring time-dependent release of the new biomarkers
showed that the new type II collagen assays could proﬁle the
degradation of cartilage as a function of time. The releases of
CIIM538 and CIIM1027 are signiﬁcantly increased when treated
with O+T for 13-15 days. These results show similar pattern to the
release observed when we measure MMP-generated aggrecan
fragments (342-G2). The third MMP-derived marker, CIIM1053,
seems to displace the release to later time points, which resem-
bles the release pattern of CTX-II. Furthermore the signal was
inhibited when MMP inhibitor, but not other protease inhibitors,
was added to the cultures.
Conclusions: We have developed three new biomarkers of type II
collagen, speciﬁc for MMP neoepitopic sites in the helical region.
These three assays display different release patterns; suggesting
the use of these in proﬁling different stages or processes of carti-
lage degradation. The combination of several markers is needed
for the understanding biological processes in preclinical settings,
and these assay aid the understanding to distinct and relevant dis-
ease related processes. In a near future, we will introduce clinical
sample to these assays in hope of developing important clinical
tools.
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Purpose: Quantitative determination of cartilage degradation is
important information for the assessment of patients with joint dis-
eases, however, until now in vitro diagnostic products have failed
to provide the necessary sensitivity and speciﬁcity. We therefore
wanted to investigate the clinical utility of a series of new sandwich
immunoassays quantitating different pools of aggrecan fragments
carrying neo-epitopes generated by the proteolytic cleavage of
aggrecanase and matrix metalloproteinases (MMPs).
